MYB and acute myeloid leukemia: Through its tAD, MYB interacts with the KIX-domain of the histone acetyl transferases p300 and CBP17–21, an interaction which is required for the induction of acute myeloid leukemia (AML) and appears to be a promising therapeutic target for AML treatment22.